We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
-10.7%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$11.7B
AUM Growth
-$3.17B
Cap. Flow
-$1.15B
Cap. Flow %
-9.88%
Top 10 Hldgs %
46.25%
Holding
136
New
17
Increased
36
Reduced
23
Closed
34

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$440M
2
IQV icon
IQVIA
IQV
+$269M
3
AGN
Allergan plc
AGN
+$247M
4
GD icon
General Dynamics
GD
+$183M
5
FIS icon
Fidelity National Information Services
FIS
+$158M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$793M
2
MDCO
Medicines Co
MDCO
+$282M
3
ZAYO
Zayo Group Holdings, Inc.
ZAYO
+$236M
4
SPGI icon
S&P Global
SPGI
+$175M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$104M

Sector Composition

Rank Sector Weight
1 Healthcare 51.69%
2 Communication Services 12.39%
3 Technology 10.92%
4 Industrials 5.44%
5 Financials 3.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
26
Alnylam Pharmaceuticals
ALNY
$29.3B
$163M 1.4%
1,500,000
+50,000
+3% +$5.77M
PANW icon
27
Palo Alto Networks
PANW
$297B
$162M 1.39%
5,920,326
-730,170
-11% -$25.5M
ASND icon
28
Ascendis Pharma A/S
ASND
$16.8B
$155M 1.33%
1,376,349
+97,349
+8% +$12.6M
TRU icon
29
TransUnion
TRU
$15.3B
$134M 1.15%
2,023,887
+496,116
+32% +$42.8M
BMY.RT
30
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$134M 1.15%
35,200,000
+4,825,050
+16% +$15.9M
QGEN icon
31
Qiagen
QGEN
$8.72B
$123M 1.06%
2,792,374
+761,032
+37% +$29.7M
FTSV
32
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$105M 0.91%
+1,105,000
New +$66.8M
ENTA icon
33
Enanta Pharmaceuticals
ENTA
$400M
$90M 0.77%
1,750,000
– –
RARX
34
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$69.1M 0.59%
1,440,000
+251,900
+21% +$11.7M
FATE icon
35
Fate Therapeutics
FATE
$326M
$66.6M 0.57%
3,000,000
+750,000
+33% +$19M
WMGI
36
DELISTED
Wright Medical Group Inc
WMGI
$65.2M 0.56%
2,275,000
+1,585,000
+230% +$47M
GRFS
37
Grifois
GRFS
$5.4B
$62.7M 0.54%
3,113,222
– –
ZYME icon
38
Zymeworks
ZYME
$1.67B
$62.1M 0.53%
1,750,000
+50,000
+3% +$2.05M
ZGNX
39
DELISTED
Zogenix, Inc.
ZGNX
$55.6M 0.48%
2,250,000
+500,000
+29% +$18.2M
KYNB
40
Kyntra Bio
KYNB
$29.4M
$55.6M 0.48%
63,987
+9,987
+18% +$9.93M
BRMK
41
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
$53.9M 0.46%
7,170,213
-4,400
-0.1% -$48.5K
APLS
42
DELISTED
Apellis Pharmaceuticals
APLS
$53.6M 0.46%
2,000,000
+1,500,000
+300% +$53.3M
PLYA
43
DELISTED
Playa Hotels & Resorts
PLYA
$53.6M 0.46%
30,606,930
– –
MRTX
44
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$46.1M 0.4%
600,000
+425,000
+243% +$38.1M
EFX icon
45
Equifax
EFX
$21.4B
$45.2M 0.39%
378,275
-273,914
-42% -$39.8M
AGIO icon
46
Agios Pharmaceuticals
AGIO
$1.93B
$44.4M 0.38%
1,250,000
– –
DCPH
47
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$41.2M 0.35%
1,000,000
+50,000
+5% +$2.78M
KRTX
48
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$40.8M 0.35%
567,047
-32,953
-5% -$2.82M
UTHR icon
49
United Therapeutics
UTHR
$23.1B
$34.6M 0.3%
+365,000
New +$34.7M
SRPT icon
50
Sarepta Therapeutics
SRPT
$1.77B
$34.2M 0.29%
+350,000
New +$40M
1
2
3 4 5

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Farallon Capital Management held 136 positions worth $11.7B, down 21% from $14.8B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Farallon Capital Management withdrew a net $1.15B in Q1 2020, closing 34 positions and reducing 23 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $793M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 38% a quarter earlier, followed by Communication Services and Technology.

Against the trend, Farallon Capital Management opened a new position in Centene worth $431M.

  • Farallon Capital Management's largest Q1 2020 buy was Centene: 7,250,000 shares worth $431M.
  • Farallon Capital Management added most to IQVIA in Q1 2020, an estimated $269M increase.
  • Farallon Capital Management's biggest Q1 2020 reduction was MyoKardia, Inc. Common Stock, cutting an estimated $104M.
  • Farallon Capital Management fully exited Wellcare Health Plans, Inc. in Q1 2020, selling an estimated $793M.
  • Farallon Capital Management's ten largest holdings make up 46% of its $11.7B portfolio in Q1 2020.
  • Farallon Capital Management opened 17 new positions and closed 34 in Q1 2020.
  • Farallon Capital Management's portfolio value fell 21% quarter-over-quarter to $11.7B.

Based on Farallon Capital Management's 13F filing for Q1 2020, filed 15 May 2020.